Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease

Keyphrases

• Chronic Kidney Disease 100%
• Fibroblast Growth Factor 23 (FGF23) 100%
• Burosumab 100%
• X-linked Hypophosphatemia 100%
• Phosphate 42%
• Skeletal Health 28%
• Vitamin D Metabolism 28%
• Clinical Trials 14%
• Pathophysiology 14%
• Cardiovascular Mortality 14%
• Vitamin D 14%
• Healing 14%
• Novel Therapeutics 14%
• Homeostasis 14%
• Targeted Therapy 14%
• Safety Profile 14%
• Targeted Intervention 14%
• Left Ventricular Hypertrophy 14%
• Mineral Metabolism 14%
• Antibody Treatment 14%
• Hypophosphatemia 14%
• Inherited Disorders 14%
• Mineral Disorders 14%
• Renal Tubule 14%
• Bone Disorders 14%
• Serum Phosphorus 14%
• Prolonged Treatment 14%
• Rickets 14%
• Tubular Reabsorption of Phosphate 14%
• CKD-MBD 14%
• Pseudofracture 14%
• Chronic Kidney Disease CKD 14%

Medicine and Dentistry

• Chronic Kidney Disease 100%
• Burosumab 100%
• X Linked Hypophosphatemic Rickets 100%
• Fibroblast Growth Factor 23 100%
• Vitamin D Metabolism 28%
• Vitamin D 14%
• Clinical Trial 14%
• Pathophysiology 14%
• Targeted Therapy 14%
• Homeostasis 14%
• Left Ventricular Hypertrophy 14%
• Mineral Metabolism 14%
• Cardiovascular Mortality 14%
• Rickets 14%
• Chronic Kidney Disease-Mineral and Bone Disorder 14%
• Diseases 14%
• Bone Disease 14%